The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Chinmay Sharma, Executive Vice President - ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Korea GSK announced on the 29th that it will begin administering the world's first respiratory syncytial virus (RSV) vaccine, Arexvy. It will be available for vaccination at hospitals and clinics ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

Adults with RSV-associated acute respiratory infection face a 2.7-fold higher risk for death within one year, according to a ...

The U.S. Food and Drug Administration has approved GSK plc (NYSE:GSK)’s asthma medication, Nucala, for expanded use in treating a form of chronic obstructive pulmonary disease (COPD), often ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

Infections from respiratory syncytial virus (RSV) in children requiring primary care led to significant societal economic costs from outpatient treatment and parental work absences in Europe ...